MERCK FOSAMAX SALES REACH $58 MIL. IN U.S. DURING THIRD QUARTER; COZAAR, CRIXIVAN NEAR $50 MIL.; PFIZER ZITHROMAX SALES MORE THAN DOUBLE TO $75 MIL. IN U.S.
Executive Summary
Merck's Fosamax is tracking for over $200 mil. in sales in the U.S. during its first full year on the market. Fosamax sales reached $58 mil. in the U.S. for the third quarter, Merck reported Oct. 16. The osteoporosis agent was launched in the U.S. in October 1995, and has generated $141 mil. in sales so far in 1996. Worldwide sales are $79 mil. for the quarter and $189 mil. for the year to date, the company said.